147 related articles for article (PubMed ID: 29540229)
21. [Impact of first-line chemotherapy on renal function in patients with advanced upper tract urothelial carcinoma].
Li X; Sheng XN; Chi ZH; Cui CL; Si L; Mao LL; Tang BX; Lian B; Wang X; Yan XQ; Li SM; Bai X; Zhou L; Kong Y; Dai J; Guo J
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2574-2578. PubMed ID: 30220142
[No Abstract] [Full Text] [Related]
22. Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience.
Kikuchi E; Miyazaki J; Yuge K; Hagiwara M; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Yamamoto S; Kinoshita H; Wakeda H; Hanai K; Nishiyama H
Jpn J Clin Oncol; 2016 Feb; 46(2):163-9. PubMed ID: 26657277
[TBL] [Abstract][Full Text] [Related]
23. [Clinical studies of chemotherapy for patients with a solitary kidney after nephroureterectomy for advanced upper urothelial transitional cell carcinoma].
Tsujimura A; Takayama H; Tsukikawa M; Imazu T; Sugao H; Takaha M
Hinyokika Kiyo; 1995 Mar; 41(3):183-9. PubMed ID: 7741070
[TBL] [Abstract][Full Text] [Related]
24. Smaller decline of renal function after nephroureterectomy predicts poorer prognosis of upper tract urothelial carcinoma: a multicentre retrospective study.
Yamada Y; Nakagawa T; Miyakawa J; Kawai T; Tabata M; Kaneko T; Taguchi S; Naito A; Hikatsu M; Sato Y; Murata T; Matsumoto A; Miyazaki H; Suzuki M; Enomoto Y; Nishimatsu H; Kondo Y; Takeuchi T; Tanaka Y; Kume H
Jpn J Clin Oncol; 2021 Oct; 51(10):1577-1586. PubMed ID: 34047345
[TBL] [Abstract][Full Text] [Related]
25. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Renal Outcomes after Cisplatin Treatment.
Latcha S; Jaimes EA; Patil S; Glezerman IG; Mehta S; Flombaum CD
Clin J Am Soc Nephrol; 2016 Jul; 11(7):1173-1179. PubMed ID: 27073199
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.
Kim YR; Lee JL; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 Jul; 76(1):141-53. PubMed ID: 26001531
[TBL] [Abstract][Full Text] [Related]
28. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.
Mense ES; Smit AAJ; Crul M; Franssen EJF
J Clin Pharm Ther; 2019 Apr; 44(2):249-257. PubMed ID: 30578577
[TBL] [Abstract][Full Text] [Related]
29. Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy.
Klöckl MC; Kasparek AK; Riedl JM; Moik F; Mollnar S; Stotz M; Szkandera J; Terbuch A; Gerger A; Niedrist T; Pichler M; Bauernhofer T; Schilcher G; Zitta S; Rosenkranz AR; Friedl C; Stöger H; Posch F
Sci Rep; 2020 Jul; 10(1):11219. PubMed ID: 32641710
[TBL] [Abstract][Full Text] [Related]
30. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
Prasaja Y; Sutandyo N; Andrajati R
Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
[TBL] [Abstract][Full Text] [Related]
31. Possible risk of overestimation of renal function using cystatin C-based eGFR in testicular cancer survivors treated with cisplatin-based chemotherapy.
Ichioka D; Kawai K; Tanaka K; Ishitsuka R; Yoshino T; Kimura T; Kandori S; Kawahara T; Kojima T; Usui J; Yamagata K; Miyazaki J; Nishiyama H
Clin Exp Nephrol; 2018 Jun; 22(3):727-734. PubMed ID: 28948387
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy.
Kos FT; Sendur MA; Aksoy S; Celik HT; Sezer S; Civelek B; Yaman S; Zengin N
Asian Pac J Cancer Prev; 2013; 14(2):1111-4. PubMed ID: 23621196
[TBL] [Abstract][Full Text] [Related]
33. Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association.
Koie T; Ohyama C; Fujimoto H; Nishiyama H; Miyazaki J; Hinotsu S; Kikuchi E; Sakura M; Inokuchi J; Hara T; ; Ohyama C; Nishiyama H; Fujisawa M; Uemura H; Fujimoto H; Suzuki K; Eto M; Hara I; Matsubara A; Nonomura N; Nakanishi H; Koie T; Kanayama H; Miki T; Fukumori T; Naito S;
Jpn J Clin Oncol; 2016 May; 46(5):468-74. PubMed ID: 26851754
[TBL] [Abstract][Full Text] [Related]
34. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
[TBL] [Abstract][Full Text] [Related]
35. Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study).
Matsui Y; Ogawa O; Ishitsuka R; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Fujie K; Keino N; Nishiyama H
Int J Clin Oncol; 2016 Dec; 21(6):1142-1149. PubMed ID: 27349431
[TBL] [Abstract][Full Text] [Related]
36. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
[TBL] [Abstract][Full Text] [Related]
37. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.
Tsao CK; Moshier E; Seng SM; Godbold J; Grossman S; Winston J; Oh WK; Galsky MD
Clin Genitourin Cancer; 2012 Mar; 10(1):15-20. PubMed ID: 22130294
[TBL] [Abstract][Full Text] [Related]
38. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
39. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma.
Rodríguez Faba O; Palou J; Breda A; Maroto P; Fernández Gómez JM; Wong A; Villavicencio H
Urol Int; 2014; 92(2):169-73. PubMed ID: 24280761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
